調査レポート | • レポートコード：GIR-2104Z11609 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥494,160 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥741,240 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥988,320 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、肺薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。肺薬の種類別市場規模（吸入コルチコステロイド、長時間作用性ベータ2作動薬、抗ヒスタミン薬、血管拡張薬、その他）、用途別市場規模（喘息・COPD、アレルギー性鼻炎、肺動脈性肺高血圧症、嚢胞性線維症、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・肺薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Sanofi SA、Meda Pharmaceuticals、Circassia Pharmaceuticals Plc.、AstraZeneca Plc.、GlaxoSmithKline Plc.、Mallinckrodt Pharmaceuticals Plc.、Cheisi Farmaceutici S.p.A、Zambon Company S.p.A、Alaxia SAS、Merck Sharp & Dohme Limited ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：吸入コルチコステロイド、長時間作用性ベータ2作動薬、抗ヒスタミン薬、血管拡張薬、その他 ・用途別分析2016年-2026年：喘息・COPD、アレルギー性鼻炎、肺動脈性肺高血圧症、嚢胞性線維症、その他 ・肺薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・肺薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・肺薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・肺薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・肺薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Pulmonary Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Pulmonary Drugs size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Pulmonary Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Pulmonary Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Others
Market segment by Application can be divided into
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
The key market players for global Pulmonary Drugs market are listed below:
Sanofi SA
Meda Pharmaceuticals
Circassia Pharmaceuticals Plc.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Mallinckrodt Pharmaceuticals Plc.
Cheisi Farmaceutici S.p.A
Zambon Company S.p.A
Alaxia SAS
Merck Sharp & Dohme Limited
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Pulmonary Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Pulmonary Drugs Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Inhaled Corticosteroids
1.2.3 Long Acting Beta-2 Agonists
1.2.4 Antihistamines
1.2.5 Vasodilators
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Pulmonary Drugs Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Asthma & COPD
1.3.3 Allergic Rhinitis
1.3.4 Pulmonary Arterial Hypertension
1.3.5 Cystic Fibrosis
1.3.6 Others
1.4 Global Pulmonary Drugs Market Size & Forecast
1.4.1 Global Pulmonary Drugs Sales in Value (2016-2026))
1.4.2 Global Pulmonary Drugs Sales in Volume (2016-2026)
1.4.3 Global Pulmonary Drugs Price by Type (2016-2026) & (USD/Unit)
1.5 Global Pulmonary Drugs Production Capacity Analysis
1.5.1 Global Pulmonary Drugs Total Production Capacity (2016-2026)
1.5.2 Global Pulmonary Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Pulmonary Drugs Market Drivers
1.6.2 Pulmonary Drugs Market Restraints
1.6.3 Pulmonary Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Sanofi SA
2.1.1 Sanofi SA Details
2.1.2 Sanofi SA Major Business
2.1.3 Sanofi SA Pulmonary Drugs Product and Services
2.1.4 Sanofi SA Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Meda Pharmaceuticals
2.2.1 Meda Pharmaceuticals Details
2.2.2 Meda Pharmaceuticals Major Business
2.2.3 Meda Pharmaceuticals Pulmonary Drugs Product and Services
2.2.4 Meda Pharmaceuticals Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Circassia Pharmaceuticals Plc.
2.3.1 Circassia Pharmaceuticals Plc. Details
2.3.2 Circassia Pharmaceuticals Plc. Major Business
2.3.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product and Services
2.3.4 Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 AstraZeneca Plc.
2.4.1 AstraZeneca Plc. Details
2.4.2 AstraZeneca Plc. Major Business
2.4.3 AstraZeneca Plc. Pulmonary Drugs Product and Services
2.4.4 AstraZeneca Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 GlaxoSmithKline Plc.
2.5.1 GlaxoSmithKline Plc. Details
2.5.2 GlaxoSmithKline Plc. Major Business
2.5.3 GlaxoSmithKline Plc. Pulmonary Drugs Product and Services
2.5.4 GlaxoSmithKline Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Mallinckrodt Pharmaceuticals Plc.
2.6.1 Mallinckrodt Pharmaceuticals Plc. Details
2.6.2 Mallinckrodt Pharmaceuticals Plc. Major Business
2.6.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product and Services
2.6.4 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Cheisi Farmaceutici S.p.A
2.7.1 Cheisi Farmaceutici S.p.A Details
2.7.2 Cheisi Farmaceutici S.p.A Major Business
2.7.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product and Services
2.7.4 Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Zambon Company S.p.A
2.8.1 Zambon Company S.p.A Details
2.8.2 Zambon Company S.p.A Major Business
2.8.3 Zambon Company S.p.A Pulmonary Drugs Product and Services
2.8.4 Zambon Company S.p.A Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.9 Alaxia SAS
2.9.1 Alaxia SAS Details
2.9.2 Alaxia SAS Major Business
2.9.3 Alaxia SAS Pulmonary Drugs Product and Services
2.9.4 Alaxia SAS Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.10 Merck Sharp & Dohme Limited
2.10.1 Merck Sharp & Dohme Limited Details
2.10.2 Merck Sharp & Dohme Limited Major Business
2.10.3 Merck Sharp & Dohme Limited Pulmonary Drugs Product and Services
2.10.4 Merck Sharp & Dohme Limited Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Pulmonary Drugs Sales by Manufacturer
3.1 Global Pulmonary Drugs Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Pulmonary Drugs Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Pulmonary Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Pulmonary Drugs Manufacturer Market Share
3.4.2 Top 6 Pulmonary Drugs Manufacturer Market Share
3.5 Global Pulmonary Drugs Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Pulmonary Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Pulmonary Drugs Market Size by Region
4.1.1 Global Pulmonary Drugs Sales in Volume by Region (2016-2026)
4.1.2 Global Pulmonary Drugs Revenue by Region (2016-2026)
4.2 North America Pulmonary Drugs Revenue (2016-2026)
4.3 Europe Pulmonary Drugs Revenue (2016-2026)
4.4 Asia-Pacific Pulmonary Drugs Revenue (2016-2026)
4.5 South America Pulmonary Drugs Revenue (2016-2026)
4.6 Middle East and Africa Pulmonary Drugs Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Pulmonary Drugs Sales in Volume by Type (2016-2026)
5.2 Global Pulmonary Drugs Revenue by Type (2016-2026)
5.3 Global Pulmonary Drugs Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Pulmonary Drugs Sales in Volume by Application (2016-2026)
6.2 Global Pulmonary Drugs Revenue by Application (2016-2026)
6.3 Global Pulmonary Drugs Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Pulmonary Drugs Sales by Type (2016-2026)
7.2 North America Pulmonary Drugs Sales by Application (2016-2026)
7.3 North America Pulmonary Drugs Market Size by Country
7.3.1 North America Pulmonary Drugs Sales in Volume by Country (2016-2026)
7.3.2 North America Pulmonary Drugs Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Pulmonary Drugs Sales by Type (2016-2026)
8.2 Europe Pulmonary Drugs Sales by Application (2016-2026)
8.3 Europe Pulmonary Drugs Market Size by Country
8.3.1 Europe Pulmonary Drugs Sales in Volume by Country (2016-2026)
8.3.2 Europe Pulmonary Drugs Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Pulmonary Drugs Sales by Type (2016-2026)
9.2 Asia-Pacific Pulmonary Drugs Sales by Application (2016-2026)
9.3 Asia-Pacific Pulmonary Drugs Market Size by Region
9.3.1 Asia-Pacific Pulmonary Drugs Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Pulmonary Drugs Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Pulmonary Drugs Sales by Type (2016-2026)
10.2 South America Pulmonary Drugs Sales by Application (2016-2026)
10.3 South America Pulmonary Drugs Market Size by Country
10.3.1 South America Pulmonary Drugs Sales in Volume by Country (2016-2026)
10.3.2 South America Pulmonary Drugs Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Pulmonary Drugs Sales by Type (2016-2026)
11.2 Middle East & Africa Pulmonary Drugs Sales by Application (2016-2026)
11.3 Middle East & Africa Pulmonary Drugs Market Size by Country
11.3.1 Middle East & Africa Pulmonary Drugs Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Pulmonary Drugs Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Pulmonary Drugs Typical Distributors
12.3 Pulmonary Drugs Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Pulmonary Drugs Revenue by Type, (USD Million), 2021-2026
Table 2. Global Pulmonary Drugs Revenue by Application, (USD Million), 2021-2026
Table 3. Sanofi SA Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi SA Major Business
Table 5. Sanofi SA Pulmonary Drugs Product and Services
Table 6. Sanofi SA Pulmonary Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Meda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 8. Meda Pharmaceuticals Major Business
Table 9. Meda Pharmaceuticals Pulmonary Drugs Product and Services
Table 10. Meda Pharmaceuticals Pulmonary Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Circassia Pharmaceuticals Plc. Basic Information, Manufacturing Base and Competitors
Table 12. Circassia Pharmaceuticals Plc. Major Business
Table 13. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product and Services
Table 14. Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. AstraZeneca Plc. Basic Information, Manufacturing Base and Competitors
Table 16. AstraZeneca Plc. Major Business
Table 17. AstraZeneca Plc. Pulmonary Drugs Product and Services
Table 18. AstraZeneca Plc. Pulmonary Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. GlaxoSmithKline Plc. Basic Information, Manufacturing Base and Competitors
Table 20. GlaxoSmithKline Plc. Major Business
Table 21. GlaxoSmithKline Plc. Pulmonary Drugs Product and Services
Table 22. GlaxoSmithKline Plc. Pulmonary Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Mallinckrodt Pharmaceuticals Plc. Basic Information, Manufacturing Base and Competitors
Table 24. Mallinckrodt Pharmaceuticals Plc. Major Business
Table 25. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product and Services
Table 26. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Cheisi Farmaceutici S.p.A Basic Information, Manufacturing Base and Competitors
Table 28. Cheisi Farmaceutici S.p.A Major Business
Table 29. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product and Services
Table 30. Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Zambon Company S.p.A Basic Information, Manufacturing Base and Competitors
Table 32. Zambon Company S.p.A Major Business
Table 33. Zambon Company S.p.A Pulmonary Drugs Product and Services
Table 34. Zambon Company S.p.A Pulmonary Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Alaxia SAS Basic Information, Manufacturing Base and Competitors
Table 36. Alaxia SAS Major Business
Table 37. Alaxia SAS Pulmonary Drugs Product and Services
Table 38. Alaxia SAS Pulmonary Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Merck Sharp & Dohme Limited Basic Information, Manufacturing Base and Competitors
Table 40. Merck Sharp & Dohme Limited Major Business
Table 41. Merck Sharp & Dohme Limited Pulmonary Drugs Product and Services
Table 42. Merck Sharp & Dohme Limited Pulmonary Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Global Pulmonary Drugs Sales by Manufacturer (2019-2021e) & (K Units)
Table 44. Global Pulmonary Drugs Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 45. Market Position of Manufacturers in Pulmonary Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 46. Global Pulmonary Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and Pulmonary Drugs Production Site of Key Manufacturer
Table 48. Global Pulmonary Drugs Sales by Region (2016-2021e) & (K Units)
Table 49. Global Pulmonary Drugs Sales by Region (2021-2026) & (K Units)
Table 50. Global Pulmonary Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 51. Global Pulmonary Drugs Revenue by Region (2021-2026) & (USD Million)
Table 52. Global Pulmonary Drugs Sales by Type (2016-2021e) & (K Units)
Table 53. Global Pulmonary Drugs Sales by Type (2021-2026) & (K Units)
Table 54. Global Pulmonary Drugs Revenue by Type (2016-2021e) & (USD Million)
Table 55. Global Pulmonary Drugs Revenue by Type (2021-2026) & (USD Million)
Table 56. Global Pulmonary Drugs Price by Type (2016-2021e) & (USD/Unit)
Table 57. Global Pulmonary Drugs Price by Type (2021-2026) & (USD/Unit)
Table 58. Global Pulmonary Drugs Sales by Application (2016-2021e) & (K Units)
Table 59. Global Pulmonary Drugs Sales by Application (2021-2026) & (K Units)
Table 60. Global Pulmonary Drugs Revenue by Application (2016-2021e) & (USD Million)
Table 61. Global Pulmonary Drugs Revenue by Application (2021-2026) & (USD Million)
Table 62. Global Pulmonary Drugs Price by Application (2016-2021e) & (USD/Unit)
Table 63. Global Pulmonary Drugs Price by Application (2021-2026) & (USD/Unit)
Table 64. North America Pulmonary Drugs Sales by Country (2016-2021e) & (K Units)
Table 65. North America Pulmonary Drugs Sales by Country (2021-2026) & (K Units)
Table 66. North America Pulmonary Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 67. North America Pulmonary Drugs Revenue by Country (2021-2026) & (USD Million)
Table 68. North America Pulmonary Drugs Sales by Type (2016-2021e) & (K Units)
Table 69. North America Pulmonary Drugs Sales by Type (2021-2026) & (K Units)
Table 70. North America Pulmonary Drugs Sales by Application (2016-2021e) & (K Units)
Table 71. North America Pulmonary Drugs Sales by Application (2021-2026) & (K Units)
Table 72. Europe Pulmonary Drugs Sales by Country (2016-2021e) & (K Units)
Table 73. Europe Pulmonary Drugs Sales by Country (2021-2026) & (K Units)
Table 74. Europe Pulmonary Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 75. Europe Pulmonary Drugs Revenue by Country (2021-2026) & (USD Million)
Table 76. Europe Pulmonary Drugs Sales by Type (2016-2021e) & (K Units)
Table 77. Europe Pulmonary Drugs Sales by Type (2021-2026) & (K Units)
Table 78. Europe Pulmonary Drugs Sales by Application (2016-2021e) & (K Units)
Table 79. Europe Pulmonary Drugs Sales by Application (2021-2026) & (K Units)
Table 80. Asia-Pacific Pulmonary Drugs Sales by Region (2016-2021e) & (K Units)
Table 81. Asia-Pacific Pulmonary Drugs Sales by Region (2021-2026) & (K Units)
Table 82. Asia-Pacific Pulmonary Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 83. Asia-Pacific Pulmonary Drugs Revenue by Region (2021-2026) & (USD Million)
Table 84. Asia-Pacific Pulmonary Drugs Sales by Type (2016-2021e) & (K Units)
Table 85. Asia-Pacific Pulmonary Drugs Sales by Type (2021-2026) & (K Units)
Table 86. Asia-Pacific Pulmonary Drugs Sales by Application (2016-2021e) & (K Units)
Table 87. Asia-Pacific Pulmonary Drugs Sales by Application (2021-2026) & (K Units)
Table 88. South America Pulmonary Drugs Sales by Country (2016-2021e) & (K Units)
Table 89. South America Pulmonary Drugs Sales by Country (2021-2026) & (K Units)
Table 90. South America Pulmonary Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 91. South America Pulmonary Drugs Revenue by Country (2021-2026) & (USD Million)
Table 92. South America Pulmonary Drugs Sales by Type (2016-2021e) & (K Units)
Table 93. South America Pulmonary Drugs Sales by Type (2021-2026) & (K Units)
Table 94. South America Pulmonary Drugs Sales by Application (2016-2021e) & (K Units)
Table 95. South America Pulmonary Drugs Sales by Application (2021-2026) & (K Units)
Table 96. Middle East & Africa Pulmonary Drugs Sales by Country (2016-2021e) & (K Units)
Table 97. Middle East & Africa Pulmonary Drugs Sales by Country (2021-2026) & (K Units)
Table 98. Middle East & Africa Pulmonary Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 99. Middle East & Africa Pulmonary Drugs Revenue by Country (2021-2026) & (USD Million)
Table 100. Middle East & Africa Pulmonary Drugs Sales by Type (2016-2021e) & (K Units)
Table 101. Middle East & Africa Pulmonary Drugs Sales by Type (2021-2026) & (K Units)
Table 102. Middle East & Africa Pulmonary Drugs Sales by Application (2016-2021e) & (K Units)
Table 103. Middle East & Africa Pulmonary Drugs Sales by Application (2021-2026) & (K Units)
Table 104. Direct Channel Pros & Cons
Table 105. Indirect Channel Pros & Cons
Table 106. Pulmonary Drugs Typical Distributors
Table 107. Pulmonary Drugs Typical Customers
List of Figures
Figure 1. Pulmonary Drugs Picture
Figure 2. Global Pulmonary Drugs Sales Market Share by Type in 2020
Figure 3. Inhaled Corticosteroids
Figure 4. Long Acting Beta-2 Agonists
Figure 5. Antihistamines
Figure 6. Vasodilators
Figure 7. Others
Figure 8. Global Pulmonary Drugs Sales Market Share by Application in 2020
Figure 9. Asthma & COPD
Figure 10. Allergic Rhinitis
Figure 11. Pulmonary Arterial Hypertension
Figure 12. Cystic Fibrosis
Figure 13. Others
Figure 14. Global Pulmonary Drugs Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 15. Global Pulmonary Drugs Market Size and Forecast (2016-2026) & (USD Million)
Figure 16. United States Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. Canada Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Mexico Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Germany Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. France Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. United Kingdom Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. Russia Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Italy Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. China Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Japan Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Korea Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. India Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Southeast Asia Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Australia Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Brazil Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Egypt Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. Saudi Arabia Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 33. South Africa Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 34. Turkey Pulmonary Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 35. Global Pulmonary Drugs Sales (2016-2026) & (K Units)
Figure 36. Global Pulmonary Drugs Production Capacity (2016-2026) & (K Units)
Figure 37. Global Pulmonary Drugs Production Capacity by Geographic Region: 2020 VS 2021
Figure 38. Pulmonary Drugs Market Drivers
Figure 39. Pulmonary Drugs Market Restraints
Figure 40. Pulmonary Drugs Market Trends
Figure 41. Global Pulmonary Drugs Sales Market Share by Manufacturer in 2020
Figure 42. Global Pulmonary Drugs Revenue Market Share by Manufacturer in 2020
Figure 43. Pulmonary Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 44. Top 3 Pulmonary Drugs Manufacturer (Revenue) Market Share in 2020
Figure 45. Top 6 Pulmonary Drugs Manufacturer (Revenue) Market Share in 2020
Figure 46. Global Pulmonary Drugs Sales Market Share by Region (2016-2026)
Figure 47. Global Pulmonary Drugs Revenue Market Share by Region (2016-2026)
Figure 48. North America Pulmonary Drugs Revenue (2016-2026) & (USD Million)
Figure 49. Europe Pulmonary Drugs Revenue (2016-2026) & (USD Million)
Figure 50. Asia-Pacific Pulmonary Drugs Revenue (2016-2026) & (USD Million)
Figure 51. South America Pulmonary Drugs Revenue (2016-2026) & (USD Million)
Figure 52. Middle East & Africa Pulmonary Drugs Revenue (2016-2026) & (USD Million)
Figure 53. Global Pulmonary Drugs Sales Market Share by Type (2016-2026)
Figure 54. Global Pulmonary Drugs Revenue Market Share by Type (2016-2026)
Figure 55. Global Pulmonary Drugs Price by Type (2016-2026) & (USD/Unit)
Figure 56. Global Pulmonary Drugs Sales Market Share by Application (2016-2026)
Figure 57. Global Pulmonary Drugs Revenue Market Share by Application (2016-2026)
Figure 58. Global Pulmonary Drugs Price by Application (2016-2026) & (USD/Unit)
Figure 59. North America Pulmonary Drugs Sales Market Share by Country (2016-2026)
Figure 60. North America Pulmonary Drugs Revenue Market Share by Country (2016-2026)
Figure 61. North America Pulmonary Drugs Sales Market Share by Type (2016-2026)
Figure 62. North America Pulmonary Drugs Sales Market Share by Application (2016-2026)
Figure 63. Europe Pulmonary Drugs Sales Market Share by Country (2016-2026)
Figure 64. Europe Pulmonary Drugs Revenue Market Share by Country (2016-2026)
Figure 65. Europe Pulmonary Drugs Sales Market Share by Type (2016-2026)
Figure 66. Europe Pulmonary Drugs Sales Market Share by Application (2016-2026)
Figure 67. Asia-Pacific Pulmonary Drugs Sales Market Share by Region (2016-2026)
Figure 68. Asia-Pacific Pulmonary Drugs Revenue Market Share by Region (2016-2026)
Figure 69. Asia-Pacific Pulmonary Drugs Sales Market Share by Region (2016-2026)
Figure 70. Asia-Pacific Pulmonary Drugs Sales Market Share by Application (2016-2026)
Figure 71. South America Pulmonary Drugs Sales Market Share by Country (2016-2026)
Figure 72. South America Pulmonary Drugs Revenue Market Share by Country (2016-2026)
Figure 73. South America Pulmonary Drugs Sales Market Share by Type (2016-2026)
Figure 74. South America Pulmonary Drugs Sales Market Share by Application (2016-2026)
Figure 75. Middle East & Africa Pulmonary Drugs Sales Market Share by Country (2016-2026)
Figure 76. Middle East & Africa Pulmonary Drugs Revenue Market Share by Country (2016-2026)
Figure 77. Middle East & Africa Pulmonary Drugs Sales Market Share by Type (2016-2026)
Figure 78. Middle East & Africa Pulmonary Drugs Sales Market Share by Application (2016-2026)
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source
世界の肺動脈性肺高血圧症治療市場規模・現状・予測（2021年-2027年） Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries re…- 世界の慢性閉塞性肺疾患（COPD）治療薬市場規模・現状・予測（2021年-2027年） Chronic obstructive pulmonary disease (COPD) is a chronic bronchitis and/or emphysema characterized by airflow obstruction, which can further develop into a common chronic disease of cor pulmona and respiratory failure.It is related to the abnormal inflammatory reaction of harmful gases and harmful …
- 世界の慢性閉塞性肺疾患（COPD）市場規模・現状・予測（2021年-2027年） Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eve…
- 世界の肺拡張用バルーン市場 2021：企業別、地域別、種類・用途別 The Pulmonary Dilation Balloon market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…
- 世界の経カテーテル肺動脈弁市場 2021：企業別、地域別、種類・用途別 The Transcatheter Pulmonary Valve market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade r…